-
-
-
-
-
-
-
Oncocyte Reports First Quarter 2023 Financial Results
-
-
-
-
-
-
-
Oncocyte Completes Validation of TheraSure™ Transplant Monitor Test
-
-
-
-
-
-
-
OncoCyte (OCX) Announces Collaboration with Gruppo Oncologico del Nord Ovest to Evaluate Oncocyte’s DetermaIO Test in Colorectal Cancer, the Second Leading Cause of Cancer Mortality Globally
-
-
-
-
-
-
-
Oncocyte to Present New Data on DetermaIO™ Test as a Predictor of Immunotherapy Response in Renal Cell Cancer at the 2021 ASCO Annual Meeting
-
-
-
-
-
-
-
Oncocyte Announces Peer-Reviewed Publication of Data Assessing Use of DetermaIO™ to Identify Patients Likely to Benefit from Immunotherapy Across Multiple Tumor Types
-
-
-
-
-
-
-
Oncocyte Announces Closing of $40 Million Public Offering of Common Stock
-
-
-
-
-
-
-
OncoCyte (OCX) Announces Proposed $25M Registered Offering
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

